Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Date:8/21/2008

> OGX-011 may reverse docetaxel resistance and improve patient

survival. In July 2008, OncoGenex Technologies reached an agreement

with the U.S. Food and Drug Administration (FDA) on the design of a

Phase 3 registration trial of OGX-011 via the Special Protocol

Assessment (SPA) process;

- OGX-427 is designed to reduce production of Hsp27, a protein that is

over-produced in response to many cancer treatments including hormone

ablation therapy, chemotherapy and radiation therapy. Hsp27

production has been shown to inhibit cell death in tumor cells

through a variety of mechanisms. OGX-427 is in a Phase 1 clinical

trial for the treatment of solid tumors including prostate, non-small

cell lung, breast, ovarian, and bladder cancers. The Company

anticipates that the safety profile for OGX-427 as a single agent

will be completed in the second half of 2008, and for OGX-427 in

combination with chemotherapy in the first half of 2009. Phase 2

clinical development will begin in 2009. Like OGX-011, this product

candidate has potential as a treatment in a broad number of cancers;

- SN2310 is a novel prodrug of SN-38, which is a potent anti-cancer

drug belonging to the class of topoisomerase I inhibitors. SN2310 is

designed to enhance the delivery and exposure of SN-38 to the tumor

by providing greater prodrug conversion and a longer half-life than

achieved with irinotecan. It is currently in a Phase 1 trial and

progress is being made to determine its safety and pharmacokinetic

profile, in addition to the maximum tolerated dose;

- CSP-9222 is a caspase activator presently in pre-clinical

development. Caspase activators consist of small molecules that have

been identified in preclinical research as activators of programmed

<
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Research and Markets has announced the addition ... Market 2014-2018" report to their offering. ... the study of the gene and its functions and ... of proteomes or sets of proteins by using molecular ... mapping of genes and DNA sequencing to understand the ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... 28 , - Guests Will ... , Staying healthy in these stressful ... Attitude Health Retreats early in 2009 may provide,participants with the ... A key component of the retreat ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , ... it received a Staff Determination Letter (the "Letter") from ... the staff of Nasdaq,s Listing Qualifications Department determined, using ... the Company,s American Depository Shares ("ADRs") would be delisted ...
... web based CTMS (Clinical Trial Management System), has ... deployed visit reports, site payments, sponsor portal and ... project will include integration to our electronic data ... as other innovative functional changes to the system ...
Cached Biology Technology:New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 3
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... gradual extinction of cold-loving species, and the European land ... from the University of Kassel in Germany and the ... that human-induced temperature increases over a 40-year period in ... the near extinction of the local land leech Xerobdella ...
... have long known that the human body runs like clockwork, ... of light and darkness. Now a team of researchers is ... activity, which could allow them to predict optimal timing for ... solar day and relieve psychosocial stress. In short, ...
... showing that dog-walking in bushland significantly reduces bird ... against the practice in sensitive bushland and conservation ... the ecological impacts of dog-walking have remained subjective ... But the first clear evidence that birds ...
Cached Biology News:Role reversal as humans suck life out of leeches 2Researchers developing device to predict proper light exposure for human health 2Researchers developing device to predict proper light exposure for human health 3A dog in the hand scares birds in the bush 2